eculizumab tma | Complement blockade for TA-TMA: lessons learned from

Keyword	CPC	PCC	Volume	Score	Length of keyword
eculizumab tma	0.17	0.5	7560	32	14
eculizumab	0.67	0.2	8788	35	10
tma	1.81	0.3	5757	55	3

Keyword	CPC	PCC	Volume	Score
eculizumab tma	1.5	1	6370	44
eculizumab manufacturer	1.01	0.2	5351	93
eculizumab mat	1.62	0.6	5798	2
eculizumab mayo	0.18	0.4	7115	42
eculizumab maintenance dose	1.74	0.1	2038	34
eculizumab target	0.55	0.1	5413	91
eculizumab torrinomedica	0.27	0.4	3863	87
eculizumab ema	0.61	0.4	1515	60
tma treatment eculizumab	1.21	0.8	4460	3
tma and eculizumab	1.56	0.1	6742	43
eculizumab for drug induced tma	2	0.1	8124	63

Search Results related to eculizumab tma on Search Engine

Complement blockade for TA-TMA: lessons learned from a large …
ashpublications.org

https://ashpublications.org/blood/article/135/13/1049/430258/Complement-blockade-for-TA-TMA-lessons-learned

WEBMar 26, 2020 · Eculizumab is an effective therapeutic strategy for HSCT recipients with high-risk TA-TMA, with improved 1-year post-HSCT survival. Subjects with a higher sC5b-9 level at the start of eculizumab therapy are less likely to respond to treatment and need more drug doses. Visual Abstract. View large Download slide. Abstract.

DA: 99 PA: 70 MOZ Rank: 45

Transplant-associated thrombotic microangiopathy: theoretical
nature.com

https://www.nature.com/articles/s41409-021-01283-0

WEBApr 19, 2021 · Consideration of eculizumab cessation should only occur after full resolution of hematologic TMA markers and full complement blockade as determined by a low CH50 level.

DA: 53 PA: 14 MOZ Rank: 14

Use of Eculizumab in Transplant-Associated Thrombotic …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568057/

WEBAug 5, 2020 · In summary, this case highlights the importance of prompt diagnosis of kidney transplant–associated TMA by a multidisciplinary TMA team and early initiation of eculizumab therapy to allow recovery of renal graft and hematologic parameters. 28 Genetic testing should also be incorporated in the workup of TMA to identify any …

DA: 1 PA: 58 MOZ Rank: 59

Efficacy and Safety of Eculizumab in the Treatment of Transplant
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856300/

WEBJan 20, 2021 · Current evidence suggests that Eculizumab improves SR and ORR in patients with TA-TMA and that Eculizumab is well tolerated. However, the number of studies is limited, and the findings are based mainly on data from observational studies.

DA: 86 PA: 48 MOZ Rank: 15

A prospective multi-institutional study of eculizumab to treat high
ashpublications.org

https://ashpublications.org/blood/article/143/12/1112/498660/A-prospective-multi-institutional-study-of

WEBMar 21, 2024 · High-risk, untreated transplant-associated thrombotic microangiopathy after HCT has a dismal outcome due to multi-organ dysfunction. Early therapy with the C5 blocker eculizumab significantly improved outcomes in patient with high-risk TA-TMA and attenuated organ dysfunction.

DA: 62 PA: 96 MOZ Rank: 5

Eculizumab precision-dosing algorithm for thrombotic …
ashpublications.org

https://ashpublications.org/bloodadvances/article/6/5/1454/483419/Eculizumab-precision-dosing-algorithm-for

WEBMar 2, 2022 · Abstract. Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal posttransplant complication of hematopoietic stem cell transplantation. We recently reported that survival for TA-TMA has been improved by early intervention with eculizumab, a complement C5 inhibitor, guided by pharmacokinetic/pharmacodynamic …

DA: 54 PA: 49 MOZ Rank: 16

Eculizumab in Transplant-Associated Thrombotic Microangiopathy
nih.gov

https://pubmed.ncbi.nlm.nih.gov/26259912/

WEBWithin the limits of this retrospective analysis, our study demonstrates that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.

DA: 71 PA: 41 MOZ Rank: 30

Use of Eculizumab in Transplant-Associated Thrombotic …
kidneymedicinejournal.org

https://www.kidneymedicinejournal.org/article/S2590-0595(20)30161-8/fulltext

WEBAug 5, 2020 · Transplant-associated thrombotic microangiopathy (TMA) in the post–organ transplantation setting occurs from a number of potential inciting factors, such as the use of calcineurin inhibitors, ischemic injury, infections, or antibody-mediated rejection leading to unchecked complement activation and end-organ damage.

DA: 81 PA: 27 MOZ Rank: 74

Eculizumab in the management of drug-induced thrombotic
nih.gov

https://pubmed.ncbi.nlm.nih.gov/36871347/

WEBDrug-induced TMA (DI-TMA) is a thrombotic microangiopathy (TMA) caused by certain drugs, usually managed by drug discontinuation and supportive measures. Data on the use of complement-inhibition with eculizumab in DI-TMA is scarce, and its benefit in cases of severe or refractory DI-TMA is unclear. ….

DA: 5 PA: 9 MOZ Rank: 65

Eculizumab in chemotherapy-induced thrombotic microangiopathy
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171698/

WEBApr 17, 2020 · Thrombotic microangiopathy (TMA) is a rare but severe complication of tumors and their chemotherapeutic treatment. We report on two patients with chemotherapy-induced TMA who were successfully treated with a short course of the terminal complement inhibitor eculizumab.

DA: 4 PA: 57 MOZ Rank: 89